Isocitrate dehydrogenases 1 and 2 () are recurrently mutated in acute myeloid leukemia (AML), but their mechanistic role in leukemogenesis is poorly understood. The inhibition of TET enzymes by D-2-hydroxyglutarate (D-2-HG), which is produced by mutant (), has been suggested to promote epigenetic deregulation during tumorigenesis. In addition, also induces a differentiation block in various cell culture and mouse models. Here we analyze the genomic methylation patterns of AML patients with using Infinium 450K data from a large AML cohort and found that is associated with pronounced DNA hypermethylation at tens of thousands of CpGs. Interestingly, however, myeloid leukemia cells overexpressing , cells that were cultured in the presence of D-2-HG or TET2 mutant AML patients did not show similar methylation changes. In further analyses, we also characterized the methylation landscapes of myeloid progenitor cells and analyzed their relationship to -associated hypermethylation. Our findings identify the differentiation state of myeloid cells, rather than inhibition of TET-mediated DNA demethylation, as a major factor of -associated hypermethylation in AML. Furthermore, our results are also important for understanding the mode of action of currently developed inhibitors.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6551656 | PMC |
http://dx.doi.org/10.15698/cst2017.10.106 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!